Ticker: BIXT

BIOXYTRAN, Inc. (PINK: BIXT) Quick take: management is advancing R&D and clinical programs while running critically low on cash. The quarter produced a small GAAP profit driven by a favorable mark-to-market on an embedded derivative, but the balance sheet shows large liabilities, heavy potential...

Bioxytran, Inc. (PINK: BIXT) recently released its financial results for the first quarter ended March 31, 2025. Here are the key highlights and insights based on the income statement. Positive Aspects: Reduction in Total Operating Expenses: Total operating expenses decreased to $515,142 from $7...